Summary of Product Characteristics Updated 01-Jul-2020 | hameln pharma ltd
Adults (including elderly) and Children:
Potassium Chloride Concentrate 15% must be diluted by adding to a large volume intravenous fluid before use. For example, 10mls diluted with not less than 500mls 0.9% Sodium Chloride Intravenous Infusion BP, or other suitable diluent, and mixed well.Dosage depends on the serum ionogram value and the acid-base state. A potassium deficiency is calculated according to the formula:MMOL Potassium = KG BW x 0.2 x 2 x (4.5 actual serum potassium (MMOL)).(The extracellular volume is calculated from the body weight in KG x 0.2).It is recommended not to exceed 2-3 MMOL potassium per kg body weight in 24 hours.Potassium sparing diuretics:
Potassium supplements should not be administered with potassium sparing diuretics (such as amiloride, spironolactone and triamterene), particularly in patients with impaired renal function. Any patients on this combination require close monitoring in order to diagnose a potential hyperkalaemic condition as soon as possible.Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists:
Patients taking ACE-inhibitors or angiotensin II receptor antagonists, especially those with impaired renal function, should be closely monitored, as the potassium sparing effect in combination with potassium infusion may result in hyperkalaemia.Ciclosporin:
Concurrent use of ciclosporin may increase the risk of hyperkalaemia.Glucose Infusion:
Concomitant use of glucose infusions in hypokalaemic patients may cause a further decrease in plasma potassium concentrations.hameln pharma ltd
Nexus, Gloucester Business Park,
Gloucester, GL3 4AG,
UK
PL 01502/0007R
22nd May 2002
01/04/2020
Nexus, Gloucester Business Park, Gloucester, GL3 4AG, UK
+44 (0)1452 621 661
https://www.hameln-pharma.com
+44 (0)1452 632 732